Holen Sie sich die Stockscreener-App
69.52
0.15%
-0.4633
Schlusskurs vom Vortag:
$69.98
Offen:
$67.865
24-Stunden-Volumen:
2.69M
Relative Volume:
2.03
Marktkapitalisierung:
$4.23B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-100.44M
KGV:
-31.31
EPS:
-2.22
Netto-Cashflow:
$-105.32M
1W Leistung:
+117.54%
1M Leistung:
+112.77%
6M Leistung:
+240.69%
1J Leistung:
+101.25%
1-Tages-Spanne:
$66.44
$71.99
1-Wochen-Bereich:
$30.94
$94.90
52-Wochen-Spanne:
$13.22
$94.90
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Firmenname
Structure Therapeutics Inc Adr
Sektor
Branche
Telefon
(650) 457-1978
Adresse
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
Vergleichen Sie GPCR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
69.73 | 4.25B | 0 | -100.44M | -105.32M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.32 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.26 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.61 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
893.75 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
194.55 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-02 | Eingeleitet | Citigroup | Buy |
| 2025-02-28 | Eingeleitet | William Blair | Outperform |
| 2025-01-08 | Eingeleitet | Stifel | Buy |
| 2024-12-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-05-21 | Eingeleitet | JP Morgan | Overweight |
| 2024-04-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-07-27 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-25 | Fortgesetzt | Jefferies | Buy |
| 2023-02-28 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-02-28 | Eingeleitet | Guggenheim | Buy |
| 2023-02-28 | Eingeleitet | Jefferies | Buy |
| 2023-02-28 | Eingeleitet | SVB Securities | Outperform |
Alle ansehen
Structure Therapeutics Inc Adr Aktie (GPCR) Neueste Nachrichten
GPCR Stock Soars 102% on Strong Phase II Obesity Data for Aleniglipron - TradingView
This trade activity should not be overlooked: Structure Therapeutics Inc ADR (GPCR) - Setenews
Biggest Stock Gainers Today in the US (Dec. 9, 2025): Wave Life Sciences, Structure Therapeutics, Confluent and More - ts2.tech
Structure Therapeutics stock hits 52-week high at 45.05 USD By Investing.com - Investing.com Canada
Why Structure Therapeutics Stock Doubled and Then Some on Monday - Finviz
Structure Therapeutics Inc. (GPCR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Structure Therapeutics Unveils Major Data Release Driving Market Buzz - StocksToTrade
Structure Therapeutics stock price target raised to $90 by Stifel - Investing.com
Mid Cap Stocks To Watch TodayDecember 8th - MarketBeat
Structure Therapeutics stock falls after $500 million share offering - Investing.com India
Structure Therapeutics launches $500 million public offering By Investing.com - Investing.com South Africa
Structure Therapeutics (NASDAQ: GPCR) plans $500M ADS sale with $75M option - Stock Titan
2 companies poised to capitalize on the rise of GLP-1 drugs - Morningstar Australia
Structure Therapeutics’ Potential Breakthrough: Market Awaits Data - StocksToTrade
Pharmaceutical Stocks To Follow TodayDecember 8th - MarketBeat
Medical Stocks To Watch TodayDecember 8th - MarketBeat
Promising Potential of Structure Therapeutics’ Aleniglipron: A Buy Rating Based on Transformative Efficacy and Strategic Innovation - TipRanks
Positive Outlook for Structure Therapeutics: Aleniglipron Shows Promising Results in Obesity Treatment - TipRanks
Structure Phase 2 data for aleniglipron look ‘competitive,’ says Morgan Stanley - TipRanks
Structure Therapeutics Stock Jumps on Trial Results for Weight-Loss Pill - The Wall Street Journal
Structure Therapeutics posts mid-stage weight-loss pill data in line with Eli Lilly rival - Sherwood News
Structure Therapeutics stock hits 52-week high at 45.05 USD - Investing.com
Structure Therapeutics Announces Positive Clinical Trial Results - TipRanks
Structure Therapeutics stock soars after strong weight loss data for oral drug - Investing.com UK
Biotech Soars On Potential 'Best-In-Class' Obesity Drug - Investor's Business Daily
Structure Therapeutics’ Stocks Surge on Promising Drug Data - TipRanks
GPCR: Aleniglipron achieved up to 15.3% weight loss at 36 weeks with strong safety and no plateau - TradingView
GPCR: Aleniglipron showed up to 15.3% weight loss at 36 weeks with strong safety and tolerability - TradingView
Structure Therapeutics (NASDAQ: GPCR) oral GLP-1 cuts weight up to 15.3% in Phase 2 data - Stock Titan
Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025 - The Manila Times
Structure Therapeutics Inc. to Announce Topline Data from ACCESS Clinical Program for Aleniglipron on December 8, 2025 - Quiver Quantitative
Structure Therapeutics (NASDAQ: GPCR) to unveil ACCESS obesity program data, host call Dec. 8 - Stock Titan
Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Sold by Capital Fund Management S.A. - Defense World
American Century Companies Inc. Cuts Position in Structure Therapeutics Inc. Sponsored ADR $GPCR - Defense World
Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 5.5%Here's Why - MarketBeat
Taking the lead: Structure Therapeutics Inc ADR (GPCR) - Setenews
BARK Inc (BARK) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Setenews
9th Circ. Mulls Pharma Exec's Use Of Forced Arbitration Law - Law360
Structure Therapeutics stock: Stifel reiterates Buy rating ahead of key data - Investing.com
Envestnet Asset Management Inc. Buys Shares of 10,676 Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Endava PLC Sponsored ADR (NYSE:DAVA) Given Consensus Rating of “Hold” by Analysts - Defense World
Tejara Capital Ltd Acquires New Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Behavioral Patterns of GPCR and Institutional Flows - news.stocktradersdaily.com
10,635 Shares in Structure Therapeutics Inc. Sponsored ADR $GPCR Acquired by DNB Asset Management AS - MarketBeat
Rhenman & Partners Asset Management AB Boosts Stock Position in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
5 Argument Sessions Bias Attys Should Watch In Dec. - Law360
A better buy-in window may exist right now for Structure Therapeutics Inc ADR (GPCR) - Setenews
Promising Potential of Structure Therapeutics’ Aleniglipron in the Incretin-Based Therapy Landscape - TipRanks
DCF Advisers LLC Makes New Investment in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Buy Rating for Structure Therapeutics, Inc.: Potential Disruption in Obesity Treatment with Amylin Agonists - TipRanks
Calif. Forecast: Tribe To Make Sovereignty Args In Labor Suit - Law360
Finanzdaten der Structure Therapeutics Inc Adr-Aktie (GPCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.22%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):